Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors

Reuters2025-12-03

Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors

Lantern Pharma Inc. has announced additional results from its completed Phase 1a dose-escalation clinical trial of LP-184, a biomarker-activated cancer drug candidate. The trial enrolled 63 heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair pathway deficiencies. The study met all primary endpoints for safety and tolerability, and established a recommended Phase 2 dose. At or above therapeutic dose levels, LP-184 demonstrated a 54% disease control rate, showing encouraging efficacy signals in DNA damage repair-deficient cancers. Results from the Phase 1a study were presented in a recent company webinar, which included detailed clinical data, patient case studies, and future development plans. Lantern Pharma is advancing multiple biomarker-guided Phase 1b/2 clinical trials in indications such as triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203887903) on December 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588041321?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588041321","market":"nz","top_or_hot":-1,"title":"Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LTRN\">Lantern Pharma Inc.</a> has announced additional results from its completed Phase 1a dose-escalation clinical trial of LP-184, a biomarker-activated cancer drug candidate. The trial enrolled 63 heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair pathway deficiencies. The study met all primary endpoints for safety and tolerability, and established a recommended Phase 2 dose. At or above therapeutic dose levels, LP-184 demonstrated a 54% disease control rate, showing encouraging efficacy signals in DNA damage repair-deficient cancers. Results from the Phase 1a study were presented in a recent company webinar, which included detailed clinical data, patient case studies, and future development plans. Lantern Pharma is advancing multiple biomarker-guided Phase 1b/2 clinical trials in indications such as triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203887903) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LTRN\">Lantern Pharma Inc.</a> has announced additional results from its completed Phase 1a dose-escalation clinical trial of LP-184, a biomarker-activated cancer drug candidate. The trial enrolled 63 heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair pathway deficiencies. The study met all primary endpoints for safety and tolerability, and established a recommended Phase 2 dose. At or above therapeutic dose levels, LP-184 demonstrated a 54% disease control rate, showing encouraging efficacy signals in DNA damage repair-deficient cancers. Results from the Phase 1a study were presented in a recent company webinar, which included detailed clinical data, patient case studies, and future development plans. Lantern Pharma is advancing multiple biomarker-guided Phase 1b/2 clinical trials in indications such as triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203887903) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLxT6VP:1","article_id":"2588041321","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588041321","pubTimestamp":1764768914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lantern Pharma Inc. has announced additional results from its completed Phase 1a dose-escalation clinical trial of LP-184, a biomarker-activated cancer drug candidate. The trial enrolled 63 heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair pathway deficiencies. The study met all primary endpoints for safety and tolerability, and established a recommended Phase 2 dose. At or above therapeutic dose levels, LP-184 demonstrated a 54% disease control rate, showing encouraging efficacy signals in DNA damage repair-deficient cancers. Results from the Phase 1a study were presented in a recent company webinar, which included detailed clinical data, patient case studies, and future development plans. Lantern Pharma is advancing multiple biomarker-guided Phase 1b/2 clinical trials in indications such as triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LTRN":"Lantern Pharma Inc."},"translate_title":"Lantern Pharma报告LP-184在晚期实体瘤中的积极1a期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTRN":0.9},"content_text":"Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors\n    \n\nLantern Pharma Inc. has announced additional results from its completed Phase 1a dose-escalation clinical trial of LP-184, a biomarker-activated cancer drug candidate. The trial enrolled 63 heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair pathway deficiencies. The study met all primary endpoints for safety and tolerability, and established a recommended Phase 2 dose. At or above therapeutic dose levels, LP-184 demonstrated a 54% disease control rate, showing encouraging efficacy signals in DNA damage repair-deficient cancers. Results from the Phase 1a study were presented in a recent company webinar, which included detailed clinical data, patient case studies, and future development plans. Lantern Pharma is advancing multiple biomarker-guided Phase 1b/2 clinical trials in indications such as triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203887903) on December 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588041321","isCrawlerRequest":true}